Savolitinib Shows Promise in Gastric Cancer: Phase II Trial Completed
HUTCHMED has completed enrollment for the registration phase of its Phase II savolitinib trial in gastric cancer patients with...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials Alzheimer's Disease Article Artificial Intelligence in Clinical Trials Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage CRO Consolidation Decentralized Clinical Trials Digital Health Technologies dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
HUTCHMED has completed enrollment for the registration phase of its Phase II savolitinib trial in gastric cancer patients with...
A study published in the Journal of Clinical Psychopharmacology revealed that patients with major depressive disorder experienced fewer psychiatric...
Achieve Life Sciences announced complete results from its ORCA-3 trial, published in JAMA Internal Medicine, demonstrating cytisinicline’s efficacy in...
Tempest Therapeutics announced that the FDA granted Orphan Drug Designation to TPST-1495 for treating Familial Adenomatous Polyposis (FAP). TPST-1495...
Compass Therapeutics has initiated the first patient dosing in an Investigator Sponsored Trial (IST) at MD Anderson Cancer Center....
Elutia Inc. launched a clinical study to gather real-world data on patient outcomes using EluPro, its FDA-cleared antibiotic-eluting bioenvelope...
In September 2024, the U.S. Food and Drug Administration (FDA) issued its final guidance titled Conducting Clinical Trials with Decentralized...
Regeneron Pharmaceuticals received a Complete Response Letter (CRL) from the FDA regarding its application to extend EYLEA HD’s dosing...
Sernova Biotherapeutics secured a CAD$4 million term loan from Navigate Private Yield Fund LP III. The loan, which matures...
ElectroCore, Inc. announced positive data from a study presented at the 2025 International Brain Injury Association World Congress, showing...